Drug
RP A601
RP A601: highest development phase Phase 1, developed by Rocket Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Rocket Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| RP-A601 NCT05885412 | Phase 1 | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) |
Latest
No recent events.
Follow RP A601 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.